INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Inovio Pharmaceuticals, Inc. (INO) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm

Core Viewpoint - A shareholder class action lawsuit has been filed against Inovio Pharmaceuticals, alleging false and misleading statements regarding the company's business and operations, particularly concerning the CELLECTRA device and the INO-3107 Biologics License Application [1] Group 1: Allegations in the Lawsuit - The lawsuit claims that Inovio's manufacturing for the CELLECTRA device was deficient [1] - It is alleged that Inovio is unlikely to submit the INO-3107 Biologics License Application to the FDA by the second half of 2024 [1] - The company reportedly lacks sufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review [1] - Consequently, the overall regulatory and commercial prospects of INO-3107 are claimed to be overstated [1]